ES028 / Elpiscience - LARVOL DELTA

Novel Bispecific Macrophage Engager (BiME) Antibodies Activate T Cells and Induce Durable Immune Memory to Suppress Tumor Growth (SITC 2025) - "Consistently, blocking T cell trafficking with FTY720 did not impair the anti-tumor efficacy of a CLDN18.2/SIRPα BiME (ES028) in the MC38-hCD47/CLDN18.2 model, suggesting the involvement of resident intratumoral T cells...Moreover, these mice also exhibited impaired growth of MC38-hCD47 tumors lacking CLDN18.2 expression, indicating induction of immune memory and antigen spreading.Conclusions BiME antibodies enhance macrophage phagocytic function and reprogram myeloid cells toward a pro-inflammatory state, leading to potent T cell activation, durable immune memory, and in vivo antigen spreading. These findings support the therapeutic potential of BiMEs as novel multifaceted macrophage-targeting agents in cancer immunotherapy."

IO biomarker • Oncology • CD8 • CLDN18 • IFNAR1 • IFNG • SIRPA